Keywords

bile acid sequestrants (BAS), fibrates, cholesterol, dyslipidemia, cholesterol absorption inhibitors, ezetimibe, HMG-CoA reductase inhibitors, hyperlipidemia, statins, PCSK9 inhibitors, icosapent ethyl (IPE)

Authors

1. El Hussein, Mohamed Toufic PhD, RN, NP
2. Sharma, Aditi RN
3. Parmar, Komal RN
4. Shelat, Krupa RN

Abstract

Abstract: Effective management of dyslipidemia is of paramount importance to prevent cardiovascular (CV) complications. Using current clinical practice guidelines is recommended to correct lipid levels and prevent further pathologic processes. This article presents an overview of treatment options for patients with dyslipidemia and CV disease, with a special focus on the following drug classes: HMG-CoA reductase inhibitors (also called statins), cholesterol absorption inhibitors (ezetimibe), bile acid sequestrants, fibrates, icosapent ethyl, and PCSK9 inhibitors.